STOCK TITAN
  1. Home
  2. Sec-filings
  3. ADMA
  4. [Form 4] ADMA BIOLOGICS, INC. Insider Trading Activity

ADMA Biologics (ADMA) CEO withholds 54,858 shares to cover RSU tax obligations

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ADMA Biologics President and CEO Adam S. Grossman reported a tax-related share disposition tied to restricted stock unit vesting. On the transaction date, 54,858 shares of common stock were withheld at $15.18 per share to satisfy mandatory tax withholding obligations, and this was explicitly noted as not an open market sale.

After this withholding, Grossman directly owned 2,204,728 shares of ADMA common stock. He also had indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, entities for which he is disclosed as a control person or managing member.

Positive

  • None.

Negative

  • None.
Insider Grossman Adam S
Role President and CEO
Type Security Shares Price Value
Tax Withholding Common Stock 54,858 $15.18 $833K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 2,204,728 shares (Direct); Common Stock — 1,143,426 shares (Indirect, See Footnote)
Footnotes (1)
  1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 3) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 1,092,470 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Grossman Adam S
(Last) (First) (Middle)
C/O ADMA BIOLOGICS, INC.
465 STATE ROUTE 17
(Street)
RAMSEY NJ 07446
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/26/2026 F 54,858(1) D $15.18 2,204,728(2)(3)(4) D
Common Stock 1,143,426 I See Footnote(5)
Common Stock 580,957 I See Footnote(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.
2. Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
3. (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
4. (continued from footnote 3) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 1,092,470 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
5. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
6. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact 03/02/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ADMA (ADMA) CEO Adam S. Grossman report in this Form 4?

Adam S. Grossman reported a tax-withholding disposition of ADMA common stock related to RSU vesting. The company withheld 54,858 shares to cover mandatory taxes, rather than executing an open market sale, while his overall share holdings remain substantial.

Was the ADMA (ADMA) CEO’s Form 4 transaction an open market sale of shares?

No, the Form 4 specifies the transaction was not an open market sale. The 54,858 shares of common stock were withheld by ADMA Biologics to satisfy mandatory tax withholding obligations arising from the vesting of restricted stock units granted to the CEO.

How many ADMA (ADMA) shares were withheld for taxes in the CEO’s Form 4?

The Form 4 shows 54,858 shares of ADMA common stock were withheld to cover tax obligations at a price of $15.18 per share. This withholding stems from vested restricted stock units and is described as a tax-withholding disposition, not an open market transaction.

How many ADMA (ADMA) shares does CEO Adam S. Grossman own directly after the transaction?

Following the tax-withholding disposition, Adam S. Grossman directly owned 2,204,728 shares of ADMA common stock. This figure reflects his direct holdings after the company withheld shares for RSU-related tax obligations, as reported for the stated transaction date.

What indirect ADMA (ADMA) shareholdings are reported for the CEO in this Form 4?

The filing reports 1,143,426 ADMA shares held indirectly through Areth, LLC and 580,957 shares held indirectly through Hariden, LLC. Footnotes identify Grossman as a control person of Areth and the managing member of Hariden, linking these indirect holdings to him.

What does the Form 4 say about the ADMA (ADMA) CEO’s RSU awards?

Footnotes describe multiple unvested RSU grants that vest quarterly over four years, subject to continued service. Upon vesting, these RSUs are to be settled in common stock. The tax-withholding disposition relates to shares from such RSU vesting events.